Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) Net Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Net Margin for 7 consecutive years, with 214.09% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 51460.0% to 214.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 57.24% through Dec 2025, up 53588.0% year-over-year, with the annual reading at 57.24% for FY2025, 53588.0% up from the prior year.
  • Net Margin for Q4 2025 was 214.09% at Beam Therapeutics, up from 1162.38% in the prior quarter.
  • The five-year high for Net Margin was 214.09% in Q4 2025, with the low at 3359333.33% in Q1 2021.
  • Average Net Margin over 5 years is 232209.62%, with a median of 685.51% recorded in 2022.
  • The sharpest move saw Net Margin plummeted -283041667bps in 2021, then soared 335851248bps in 2022.
  • Over 5 years, Net Margin stood at 126.71% in 2021, then crashed by -51bps to 191.39% in 2022, then surged by 124bps to 45.16% in 2023, then crashed by -765bps to 300.51% in 2024, then soared by 171bps to 214.09% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 214.09%, 1162.38%, and 1208.26% for Q4 2025, Q3 2025, and Q2 2025 respectively.